References
1. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of
primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through
1989. Blood. 1992;79(7):1817-1822.
2. Yakupova EI, Bobyleva LG, Vikhlyantsev IM, Bobylev AG. Congo Red and
amyloids: history and relationship. Biosci Rep. 2019;39(1):BSR20181415.
Published 2019 Jan 15. doi:10.1042/BSR20181415.
3. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis
and treatment of cardiac amyloidosis. Expert Rev Cardiovasc Ther.
2015;13(11):1195-1211. doi:10.1586/14779072.2015.1093936.
4. Merlini G, Palladini G. Differential diagnosis of monoclonal
gammopathy of undetermined significance. Hematology Am Soc Hematol Educ
Program. 2012; 2012:595-603. doi:10.1182/asheducation-2012.1.595.
5. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in
2020. Hematology Am Soc Hematol Educ Program. 2020;2020(1):363-371.
doi:10.1182/hematology.2020006913.
6. Palladini G, Merlini G. What is new in diagnosis and management of
light chain amyloidosis?. Blood. 2016;128(2):159-168.
doi:10.1182/blood-2016-01-629790.
7. Bochtler T, Hegenbart U, Cremer FW, et al. Evaluation of the
cytogenetic aberration pattern in amyloid light chain amyloidosis as
compared with monoclonal gammopathy of undetermined significance reveals
common pathways of karyotypic instability. Blood. 2008;111(9):4700-4705.
doi:10.1182/blood-2007-11-12210.
8. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors
of voltage valid in cardiac amyloidosis? A contemporary analysis of
electrocardiographic findings. Int J Cardiol. 2016;214:477-481.
doi:10.1016/j.ijcard.2016.04.030.
9. Oda S, Kidoh M, Nagayama Y, et al. Trends in Diagnostic Imaging of
Cardiac Amyloidosis: Emerging Knowledge and Concepts. Radiographics.
2020;40(4):961-981. doi:10.1148/rg.2020190069.
10. Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic
sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur
Heart J. 2017;38(24):1905-1908. doi:10.1093/eurheartj/ehx047.
11. Saha A, Theis JD, Vrana JA, Dubey NK, Batra VV, Sethi S. AA
amyloidosis associated with hepatitis B. Nephrol Dial Transplant.
2011;26(7):2407-2412. doi:10.1093/ndt/gfr224.
12. Denman J, Manavi K, Cook M. Lenalidomide as a treatment for relapsed
AL amyloidosis in an HIV-positive patient. Int J STD AIDS.
2017;28(10):1045-1047. doi:10.1177/095646241769456.
13. Mansour M, Moustapha C, Maria F et al. Multiple Myeloma Secondary to
HIV Infection, Revealed by Renal Failure: About a Case. Open J Nephrol.
2019;9:20-25. doi:
10.4236/ojneph.2019.91002.
14. Breillat P, Pourcher V, Deshayes S, et al. AA Amyloidosis in the
Course of HIV Infection: A Report of 19 Cases Including 4 New French
Cases and a Comprehensive Review of Literature. Nephron.
2021;145(6):675-683. doi:10.1159/000516982.
15 Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM.
HIV-associated monoclonal gammopathy: a retrospective analysis of 25
patients. Clin Infect Dis. 2006;43(9):1198-1205. doi:10.1086/508351.